William Guyer - 10 Aug 2026 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Reporting relationship: Chief Development Officer
Issuer ticker: CORT
Reported as of: 10 Aug 2026
Net transaction value: -$1,848,890
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:26:08 UTC
Prior SEC filing: 06 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer

Key filing fact

William Guyer filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 12 Aug 2026.

Key facts

This page summarizes William Guyer's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Aug 2026, 16:26.

Change

Previous filing in this sequence was filed on 06 Aug 2026.
Current net transaction value: -$1,848,890.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001879013 Primary reporting owner

Guyer William

Relationship: Chief Development Officer
Address: C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CORT transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,300
Change %: +409%
Price: $21.65^*
Shares after: 20,285
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1

CORT transaction

Common Stock

Sale

Transaction value: $1,304,933
Shares: -11,530
Change %: -57%
Price: $113.18
Shares after: 8,755
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

CORT transaction

Common Stock

Sale

Transaction value: $543,957
Shares: -4,770
Change %: -54%
Price: $114.04
Shares after: 3,985
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CORT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -16,300
Change %: -13%
Price: $0.000000^*
Shares after: 110,000
Date: 10 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,300
Exercise price: $21.65
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F2

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

Footnote F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F4

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F5

Fully exercisable.

SEC remarks

The power of attorney under which this form was signed is on file with the Commission.